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2Abstract16
A potent anti-cancer complex has previously been formed from two major17
components of milk. Human/Bovine α-Lactalbumin made lethal to tumour cells 18 
(H/BAMLET) is a protein-fatty acid complex that has been produced using the whey19
protein α-lactalbumin (α-LA), and the fatty acid oleic acid (OA). It was shown that it 20 
possesses selective anti-tumour and anti-microbial activity, which was first identified21
in acidic fractions of human breast milk. The aim of this study was to determine22
whether the two components would form a bioactive complex during simulated23
gastric (GI) transit. Results showed that a complex consisting of α-LA and OA is 24 
formed as the protein unfolds under acidic conditions and subsequently refolds upon25
pH increase. Analysis of this complex using Nuclear Magnetic Resonance (NMR) and26
Fourier Transform Infra-Red (FTIR) spectroscopies estimated a stoichiometry of 4.127
and 4.4 oleic acids per mole of protein respectively. FTIR and fluorescence28
spectroscopies showed that the structure was similar to that of BAMLET.29
Cytotoxicity testing against cancer cell line U937 cells showed that the complex had30
an LC50 value of 14.08 M, compared to 9.15 M for BAMLET. These findings31
suggest that a BAMLET-like complex may be formed under the tested in vitro GI32
conditions.33
3Abbreviations:34
BAMLET: BAMLET produced through chromatography35
α-LA: Holo α-LA at pH 7 36 
Gastric α-LA: Partially digested α-LA in the gastric phase at pH 2.5 37 
Post-gastric α-LA: Partially digested α-LA after increase to pH 7 38 
OA: Oleic acid39
FTIR: Fourier Transform Infra-red Spectroscopy40
NMR: Nuclear Magnetic Resonance41
ANS: 8-anilino-1-naphthanene sulfonate42
BSSL: Bile Salt Stimulated Lipase43
44
45
4Introduction46
HAMLET, Human Alpha-Lactalbumin Made LEthal to Tumour cells is a protein-fatty47
acid complex between partially unfolded α-LA and OA. HAMLET was discovered by 48 
serendipity in 1995 when screening human milk for its anti-infective properties49
(Hakansson et al. 1995). Since then the field of HAMLET has expanded greatly to50
include many structural (Gustafsson et al. 2005; Pettersson-Kastberg et al. 2009;51
Pettersson-Kastberg et al. 2009) and functional (Duringer et al. 2003; Hallgren et al.52
2006; Aits et al. 2009) studies of the complex. To date it is known that HAMLET can53
kill a range of over 40 different cancer cell lines with some specificity, while having54
little or no detrimental effect on healthy, differentiated cells (Mok et al. 2007).55
HAMLET acts with an apoptosis-like mechanism. It induces microautophagy in cells56
(Aits et al. 2009) and activates caspases (Duringer et al. 2003). However it has also57
been shown that cell death is independent of caspase activation (Hallgren et al. 2006).58
HAMLET also has anti-microbial activity against Streptococcus pneumonia59
(Hakansson et al. 2000). The activity of HAMLET was tested in several in vivo60
clinical trials and it was observed that through application of HAMLET to bladder61
cancer (Mossberg et al. 2007), (Mossberg et al. 2010), skin pappilomas (Gustafsson et62
al. 2004) and also brain glioblastoma xenografts (Fischer et al. 2004), all of which a63
decrease in tumour size was observed with no effect on the healthy surrounding64
tissues.65
66
HAMLET-like complexes have also been previously formed from the α-LA of milk 67 
from other mammals including caprine and ovine, with the most notable species68
variation being bovine α-LA, denoted BAMLET (Pettersson et al. 2006), which is69
5used by a number of different research groups (Liskova et al. 2010; Rammer et al.70
2010; Spolaore et al. 2010).71
72
α-LA is a small (Mw 14,200 Da), acidic (pI ~4.8), globular protein found in the whey73
fraction of the milk of all mammals. α-LA contains four disulphide bridges cross-74 
linking the polypeptide chain. One of the disulphide bonds bridges the large α-helical 75 
domain and the smaller β-sheet domains thereby forming the calcium binding loop. 76 
The calcium is bound to the protein through aspartic acid (Asp) residues. However77
when the pH of the protein decreases below its isoelectric point these Asp residues78
start to become protonated and release the calcium thus leaving the protein in a79
partially unfolded state (Kuwajima et al, 1980). This unfolding also leaves the80
hydrophobic core exposed and this was confirmed through fluorescence studies by81
(Rösner and Redfield, 2009). This partially unfolded α-LA is structurally similar to 82 
the apo (calcium free form) and is dubbed the A-state or acid-state (Kuwajima, 1996).83
84
The main biological function of α-LA is to specify the substrate for lactose synthesis 85 
in the mammary gland (Brew et al. 1968). A follow-up clinical trial with mice where86
the gene that expressed α-LA was removed, the mice did not produce any α-LA or 87 
lactose in their milk (Stinnakre et al. 1994). A second and equally important function88
of α-LA is that it is nutritionally significant for nourishment, growth and 89 
development, particularly in humans. The amino acid profile of α-LA delivers most of 90 
the essential amino acids in the required concentrations needed for neonatal91
development.92
93
6The protein composition of human milk is also of significant importance. α-LA is the 94 
predominant protein in human milk, present at concentrations of 2-3 gL-1 (Lönnerdal95
2003). Similarly oleic acid is the most abundant fatty acid (as glycerides) in human96
milk and accounts for 34% of all fat (Gibson and Kneebone, 1981). Indigenously97
present in human milk is bile salt stimulated lipase (BSSL), which has lipolytic98
activity in the stomach, increasing lipolysis levels in both the stomach and intestines99
of infants (Jensen, 1995).100
101
Monitoring the pH profile in early infants stomachs shows that the pH remains102
elevated (Mitchell et al. 2001) and above the required pH levels for proteolysis with103
pepsin (Favilla et al. 1997), thus there is a relatively low rate of proteolysis in the104
stomach of infants. Low proteolysis levels results in polypeptide chain stability and105
presence of significant amounts of native α-LA as milk passes through the stomach 106 
phase of gastric digestion.107
108
The conditions under which HAMLET was initially discovered were similar to those109
in the stomach (Svensson et al. 2000; Barbana et al. 2006). Given that the110
composition of human milk may lend itself to the formation of HAMLET – high α-111 
LA levels, high OA levels and high gastric lipolysis – there has been speculation that112
a HAMLET-like complex may be formed in the gastric tract of breast-fed infants.113
114
The aim of this study was to determine if a BAMLET-like complex could be formed115
under simulated gastric conditions. Fractions were produced and analysed for116
structural and biological similarities to characterised BAMLET – monomeric with117
7approximately 5 times molar excess of oleic acid, produced using the previously118
published chromatographical method as a reference.119
120
Materials and methods121
122
Materials123
BioPURE-Alphalactalbumin™ (95% protein; 5% β-lactoglobulin) was purchased 124 
from Davisco Foods International Inc. (Minnesota, USA); Diethylaminoethyl (DEAE)125
Trisacryl ion exchange matrix was purchased from Pall Corp. (France); alamarBlue126
assay was purchased from Invitrogen (California, USA); Bio-Rad Protein Assay and127
molecular weight markers for SDS-PAGE from Bio-Rad Laboratories (Hertfordshire,128
UK). Unless otherwise stated all other chemicals and reagents were purchased from129
Sigma-Aldrich.130
131
Methods132
BAMLET Production133
A stock of BAMLET was produced using the previously published chromatography134
method of (Svensson et al. 2000). Briefly, apo α-LA was injected on a DEAE-135 
Trisacryl ion exchange column that was preconditioned with oleic acid. BAMLET136
fractions were eluted using 1M NaCl, dialysed against distilled and deionised H2O,137
lyophilised and stored at -20°C before analysis.138
139
Simulated digestion140
An in vitro gastric model was used. Simulated digestion experiments were performed141
at 37°C. Porcine pepsin (P7000, Sigma-Aldrich, Ireland), activity 653 U/mg protein142
8using haemoglobin as a substrate (Sigma Aldrich, 10-30-8378), was used at an E:S143
ratio of 1:100. The pH of the digest was controlled as per Figure 1 using a computer144
controlled Tiamo 842 pH monitoring and titration system (Metrohm) equipped with a145
pH probe for protein analysis. pH was maintained using 1M HCl and 1M NaOH. The146
pH gradient was used to effectively mimic the pH of the stomach of infants during147
and after feeding (Mitchell, McClure et al. 2001). Homogeneity of the digest was148
maintained through the use of a submergible stirrer at a rate of 80 rpm. Digestions149
were monitored for 2 hours with samples taken at regular time points for analysis.150
151
To formulate the test milk, α-LA was dissolved at a concentration of 700 M. CaCl2152
was added at a concentration of 0.986 M to ensure α-LA was in the holo 153 
conformation. OA was dissolved in ethanol to solubilise the fatty acid and the FA-154
ethanol emulsion was added to the α-LA to give a final OA concentration of 70 mM. 155 
Samples were taken at T0 (α-LA), in the gastric phase at pH 2.5 (α-LA pH 2.5) and 156 
when the pH of the mixture was increased to pH 7 (post-gastric α-LA pH 7). Each 157 
sample was dialysed against distilled and deionised water at 4°C, lyophilised and158
stored at -20°C prior to resolubilisation at differing concentrations prior to analysis.159
160
Fluorescence Spectroscopy161
Fluorescence measurements were performed using a Cary Eclipse Fluorescence162
Spectrophotometer equipped with a multicell holder, peltier unit and temperature163
controller. Protein concentrations were determined by the method of Bradford and the164
protein concentration of the samples was diluted to 5 μM in the appropriate buffer. 165 
Spectra were recorded at 25°C and at a scanning speed of 80 nm/min. The excitation166
and emission slits were set to 10 mm.167
9Intrinsic fluorescence168
Samples were dissolved in 10 mM Tris.HCl buffer, pH 8.5. Samples were excited at169
280 nm and emissions were recorded between 300 and 420 nm.170
ANS fluorescence171
Samples were dissolved in 10 mM Tris.HCl buffer, pH 8.5 and ANS dye was added to172
samples at a concentration of 10 μM and left to incubate at room temperature for 30 173 
minutes. The samples were then excited at 390 nm and emissions were recorded174
between 410 and 600 nm.175
Thioflavin T (ThT) fluorescence176
ThT was dissolved in 10 mL phosphate buffer (10 mM Na2HPO4; 150 mM NaCl),177
filtered through a 0.2 μM syringe filter and stored in the dark. On the day of testing  178 
1 mL of this stock was added to 50 mL phosphate buffer. The fluorescence of the179
working buffer was measured with an excitation wavelength of 440 nm and emissions180
were recorded between 470 and 550 nm. 15 μL of the native protein solution was 181 
added to the working buffer and the spectra were recorded. This procedure was182
repeated for protein complexes. An increase in intensity between the control and test183
sample is indicative of amyloid formation.184
185
Fourier Transform Infra-Red Spectroscopy (FTIR)186
FTIR measurements were performed using a Bruker Tensor 27 instrument equipped187
with a thermally controlled BioATR Cell™ II (Bruker Optik, Germany) which was188
designed for analysis of protein in solution. Measurements were performed at 20°C189
and an average of 180 scans at a resolution of 4 cm-1 were recorded. Protein samples190
were diluted to a concentration of 700 M and filtered through a 0.1 μM syringe filter. 191 
Data was processed by performing atmospheric compensation and then vector192
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normalisation at 1600-1720 cm-1 for the Amide I region, and 2800-2900 cm-1 for the193
oleic acid region. Spectra capturing software Opus (version 5.5) was used for data194
processing. The molar ratios of oleic acid to α-LA were determined using a 195 
multivariate calibration method that was developed using OPUS/QUANT software.196
197
Nuclear Magnetic Resonance Spectroscopy (NMR)198
1H NMR spectra were obtained using a 600 MHz Ultrashield NMR199
Spectrophotometer (14.1 Tesla magnetic field strength) with an indirect detection200
cryoprobe (Bruker BioSpin, Germany). Samples were prepared to a concentration of 1201
mM in 10% D2O. 1,4-Dioxane was used as an internal standard. Spectra were202
obtained at 25°C. The stoichiometry of the protein-fatty acid complexes was203
determined using integration of the peak areas for the aromatic region of the protein204
and the region where oleic acid binds.205
High-Pressure Liquid Chromatography (HPLC)206
All HPLC experiments were performed on a Waters 2695 Separations Module207
equipped with a dual wavelength detector set at 214 nm and 280 nm. Where208
applicable the column-oven was kept at 28°C. The sample chamber was set at 10°C.209
A sample volume of 20 µL of a 20 M protein solution was injected onto the column.210
Reversed-phase HPLC (RP-HPLC)211
The two solvents used for RP experiments were 0.1% TFA in MilliQ™ (A) and 90%212
MeCN, 0.1% TFA in MilliQ™ (B).213
For native protein analysis RP-C5 was performed using a SourceRPC5 column. The214
starting conditions of solvents were 60:40 A:B with a runtime of 34.1 minutes.215
For peptide analysis a μSymmetry C18 column was used. The starting conditions of 216 
solvents were 100:0 A:B with a runtime of 30 minutes.217
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Size Exclusion Chromatography (SEC)218
Digestion progression was monitored through SEC-HPLC using a TSK G2000219
column. The flow was isocratic and the solvent used was 30% MeCN with 0.1% TFA.220
There was a flowrate of 0.5 mlmin-1 and a runtime of 60 minutes.221
222
Electrophoresis223
SDS-PAGE was performed as per the method of (Laemmli 1970). The gels were224
prepared to a concentration of 20% acrylamide. Samples were dissolved at a225
concentration of 700 M and diluted 1:8 with reducing SDS-PAGE buffer. Samples226
were heated at 95°C for 5 minutes and cooled at room temperature. Molecular weight227
markers (BioRad, 161-0373, MW range 250 kDa – 10 kDa) were used as a reference228
for molecular weights.229
230
Cell viability assay231
Cytotoxicity measurements were performed using U937 cells – a suspension cell line232
extracted from a human diffuse histiocytic lymphoma. Cell were grown at a density of233
1 x 105 in RPMI 1640 supplemented with 10% fetal bovine serum and incubated at234
5% CO2 at 37°C. For cytotoxicity assays cells were subcultured at a density of 2 x235
105. Samples for cytotoxicity analysis were dissolved in RPMI 1640 and sterile236
filtered with a 0.1 μM syringe filtered and diluted to a concentration of 352 M.237
Samples were then diluted to desired concentrations between 0 and 176 M with238
RPMI to give a final volume of 50 L. Cells at a density of 2 x 105 were then added to239
the samples in the well to give a final volume of 100 L with final FBS concentration240
at 5%. Plates were incubated for 24 hours and 10 L of alamarBlue reagent was added241
to each well and the plate was incubated for 4 hours. The fluorescence intensities of242
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the samples were measured with an excitation wavelength of 530 nm and emissions243
were recorded at 590 nm. For samples with digestive enzymes present, pepstatin, a244
potent pepsin inhibitor was used to inhibit enzyme activity during bioactivity testing.245
246
Apoptosis testing247
The type of cell death occurring after treatment with samples was analyzed using a248
Cell Death Detection ELISAPLUS kit from Roche Applied Science. Cells were seeded249
and supplemented with different samples in the same manner as for cytotoxicity250
assay. After 4 h of incubation at 37 °C and 5% CO2, the cell viability was determined251
with a Trypan blue assay. Cells with 50%viability were used for the apoptosis assay.252
253
Ultrafiltration254
A stirred-cell dead-end ultrafiltration unit (Millipore) equipped with a 10 kDa255
membrane was used to separate native protein from low molecular weight compounds256
such as peptides and free oleic acid. The pressure and flowrate were controlled using257
nitrogen gas at a pressure of 1 psi, which gave a flowrate of 1 mLmin-1. A diafiltration258
step was performed by flushing the cell with MilliQ™ water. Fractions were collected259
and freeze-dried for analysis.260
261
Gas Chromatography262
The OA content of the complexes were determined as described by Palmquist and263
Jenkins, 2003. An OA standard curve was prepared by adding 0, 10, 25 and 50 µL OA264
dissolved in dichloromethane (11.7 mM) to separate tubes. As an internal standard 50265
µL palmitic acid dissolved in dichloromethane (23.5 mM) were added to each tube266
used for the standard curve and to the tubes used for test samples. After evaporation267
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of dichloromethane in a fume cupboard for 30 min, 100 µL PBS was added to the OA268
tubes and 100 µL of the protein complexes (BAMLET and digested complex) were269
added to the test samples tubes. To prepare derivatives of OA and palmitic acid for270
gas chromatography (GC) methyl esters were formed by the addition of 1.5 mL 10%271
methanolic HCl (prepared by slowly adding 20 mL acetyl chloride to 100 mL of dry272
methanol while stirring), and 1 mL heptane to each tube followed by heating to 90°C273
for 2 hours. After cooling on ice, 1 mL heptane and 3 mL 10% K2CO3 were added to274
each tube followed by vortexing and centrifugation (500g, 5 min). The heptane phase275
(upper phase) containing the fatty acid methyl esters was transferred to GC vials.276
Samples were analysed on a HP 6890 GC-system (Hewlett Packard Co., Palo Alto,277
CA, USA) with a flame-ionisation detector and a Restek Rt 2560 column (100 m x278
0.25 mm x 0.2 µM, Restek U.S., Bellefonte, PA, USA). The inlet temperature was279
275°C with a split ratio 40:1, and the carrier gas helium with a constant flow of 1.5280
mL per minute. The starting temperature of 140°C was held for 5 minutes and281
increased by 4°C per minute to an end temperature of °C. The detector temperature282
was 300°C. Results were displayed as mg oleic acid per mg of powder thus to283
quantitate the oleic acid content in the samples the mg protein per mg of powder was284
determined using the Bradford method and molarities were determined on this basis.285
286
Results287
A simulated gastric model was used for simulated digestion. In vitro models such as288
the US Pharmacopeia use static models with a set incubation time at pH 2. However289
in vivo data from neonates show a more gradual decrease in gastric pH (Mitchell,290
McClure et al. 2001). Therefore a model which employed a pH curve was used in291
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order to allow sufficient time for indigenous lipase to act, protein to unfold and a292
small amount of proteolysis to occur.293
294
Simulated digestion295
The pH of the stomach of infants was mimicked according to the pH gradient in296
Figure 1A, as per the study of Mitchell et al. This gradient represents several different297
studies where gastric pH levels were monitored during feeding. Pepsin has an298
optimum activity of between pH 1.8 and pH 2. While these pH conditions are not299
favourable for proteolytic hydrolysis they are ideal for gastric lipolysis. Gastric lipase300
enzymes are active between pH 4 and pH, 6 thus high levels of lipolysis occurs in the301
stomach of breast-fed infants due to the presence of BSSL.302
303
Structural analysis of the complex304
Fluorescence Studies305
It was previously shown by Svensson et al (2003) that α-LA unfolding is a pre-306 
requisite for the conversion of α-LA to its bioactive form. Typically Ca
2+ chelators are307
used to induce the partially unfolded apo form of α-LA. However in this study the A-308 
state of α-LA, a structurally similar form of α-LA, was induced under these acidic 309 
conditions. Unfolding was observed after acidification of α-LA during the simulated 310 
gastric phase below pH 4. This was confirmed through the comparison of the311
fluorescence spectra for holo α-LA and apo α-LA (Figure 2A). When the gastric pH 312 
model experienced a pH increase, this resulted in a reverse conformational change313
towards a partially re-folded structure (Figure 2B).314
315
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Using ANS it is possible to detect changes in the surface hydrophobicity of the316
protein (Pettersson-Kastberg, Mossberg et al. 2009). ANS binds to holo α-LA in 317 
limited amounts, however there is an increase in hydrophobicity as the molecular state318
of the protein changes from holo to apo, and a further increase in hydrophobicity319
between apo α-LA and α-LA in the A-state (Figure 2C). This suggests a higher level 320 
of hydrophobic residues exposed thus a marked increase in surface hydrophobicity.321
322
ThioflavinT (ThT) fluorescence is a rapid screening method for the detection of323
extended β-sheets such as those seen in amyloid fibrils. Any treatment of proteins that 324 
changes their structure or functionality can also increase the risk of amyloid-like325
formation, which would be a negative characteristic of proteins due to the association326
of fibrils with degenerative diseases such as Alzheimer’s and dementia (Dobson327
1999). For both the BAMLET produced through chromatography and the complex328
extracted from the simulated gastric conditions (data not shown) there was no increase329
in intensity at 490 nm, which is indicative that OA does not promote amyloid fibril330
formation under these conditions.331
332
Through intrinsic fluorescence it was shown that BAMLET and α-LA:pH 7 have a 333 
similar tertiary structure. Their secondary structure was also deemed to be similar thus334
it is a fair assumption that their respective spectra for ANS fluorescence would be335
alike. However this was not the case. This would suggest that ANS not only binds to336
the hydrophobic regions of the protein, but also the hydrophobic fatty acid oleic acid.337
This is further insinuated when the oleic acid stoichiometries for the respective338
complexes are examined as this appears to be the sole difference in the two339
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complexes. BAMLET has a higher molar ratio of OA bound (see OA quantification340
data, Figure 4, Figure 5) and also a higher ANS fluorescence intensity.341
342
FTIR343
FTIR detects changes in the secondary structure of proteins by measuring changes in344
the Amide I band (1600-1720 cm-1) which measure C=O stretching which gives345
information on the conformation of the protein. α-LA has a mainly α-helical structure 346 
thus has a peak at 1652 in the Amide I region of the FTIR spectra. Under acidic347
conditions there is a shift in the absorbance maximum of α-LA. A random coil 348 
formation, as would be observed when the protein is in its molten globule state and349
lacks 2°- or 3°- structure, has a maximum intensity at 1645 cm-1. α-LA at pH 2.5 350 
under simulated gastric conditions has a maximum intensity at 1647 cm-1 suggesting351
that it is in the molten globule-like form, which is in agreement with both intrinsic and352
ANS fluorescence. These secondary structure results are in agreement with the353
tertiary structures measured with intrinsic fluorescence, and as with intrinsic354
fluorescence, the digested complex and BAMLET have a similar secondary structure.355
This corroborates the hypothesis that a BAMLET-like complex is formed under356
simulated gastric conditions (Figure 3).357
358
NMR359
The aliphatic region of the spectra, from 0 to -1 ppm, corresponding to the δCH3360
protons of Ile and the γCH3 protons of Val residues, provides information on the361
structure and folding of the protein (Wijesinha-Bettoni, Dobson et al. 2001;362
Pettersson-Kastberg, Aits et al. 2009). Comparing spectra (a) from holo α-LA to α-LA 363 
in its molten globule form at pH 2.5 (spectra d) shows that the molten globule form364
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lacks any well-defined and 3° structure, which is characterised by the smooth line,365
whereas the spectra for holo α-LA, which has a series of peaks corresponding to its 366 
defined tertiary structure. The BAMLET complex that was produced through367
chromatography exhibits native like-structure compared to the molten globule form,368
although it is possible that there exists a partitioning of the population of protein369
molecules into native and molten globule states(Pettersson-Kastberg, Aits et al. 2009).370
It should be noted that column-BAMLET possesses cytotoxic activity, and the same371
was observed for the digested complex after the pH increase post-gastric phase of372
digestion, (Figure 4). This would suggest that structurally, it is possible that the373
partially unfolded state of the protein may coexist in equilibrium with the native state374
of molecules within the ensemble of the protein-fatty acid complex.375
376
Oleic acid content377
FTIR378
Analysis of the FTIR spectra for α-LA, OA and BAMLET shows that a band at wave 379 
number 2854 cm-1 which corresponds to OA that is not present in α-LA but is present 380 
in BAMLET. Thus FTIR can detect the presence of oleic acid, and subsequently381
quantify the oleic acid content within the samples.382
383
When α-LA is in its molten globule or apo form it is in the required conformation to 384 
bind to oleic acid and form a BAMLET-like complex. Under simulated gastric385
conditions at pH 2.5 there minimal levels of oleic acid were present. This suggests386
that hydrophobic interactions alone are not enough to bind oleic acid to α-LA. When 387 
the pH of the digest increased, α-LA refolded (Figure 5A). FTIR data suggests that 388 
there is a higher quantity of oleic acid present. Quantification of this oleic acid peak389
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gives an oleic acid stoichiometry of 4.4 moles of oleic acid per mole of α-LA. 390 
Quantification of the BAMLET sample produced through chromatography yields an391
oleic acid stoichiometry of 5.8, which is in line with the previously published392
literature of 5.4 with GC (Svensson et al, 2003) and 5.1 with NMR (Fast et al, 2005).393
394
Evaluation of the ultrafiltration permeate and retentate showed that there was oleic395
acid present in fractions of the ultrafiltrate. This would suggest that oleic acid that is396
present in the retentate is bound to the protein as free oleic acid has been removed397
through the diafiltration step. The permeate contained the highest amount of oleic acid398
and also the low molecular weight fractions of the digest. (Figure 5B).399
400
NMR401
Nuclear Magnetic Resonance has previously been used to quantify oleic acid content402
in HAMLET and HAMLET-like complexes. By integrating the peak area of both the403
aromatic region of the protein (6-10 ppm) and the peak area of the olefinic oleic acid404
region (5-5.5 ppm) it is possible to quantify the amount of oleic acid present in405
samples. What distinguishes NMR from techniques such as GC and FTIR for OA406
quantification is that it can differentiate between bound and unbound oleic acid in407
samples rather than just determining if it is present in the samples. Oleic acid that is408
bound to protein has a chemical shift of 5.3 ppm whereas free, unbound oleic acid has409
a chemical shift of 5.4 ppm (Fast et al, 2007).410
411
Analysis of both the column BAMLET and the digested complex show that the OA412
peak has a chemical shift of 5.3 ppm, verifying that the oleic acid is bound to the413
protein and not just in solution. Quantification of the oleic acid region of the digested414
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complex shows that there is a 4.1 molar excess of oleic acid bound per mole of415
protein, as compared to 5.6 for BAMLET produced through chromatography.416
417
Gas Chromatography418
Use of gas chromatography for quantification of oleic acid content in samples yielded419
results of BAMLET 11.54 mole OA/mole protein, and for α-LA-pH 7 6.84 mole 420 
OA/mole protein. This was extensively tested and it is thought that there is a lack of421
sensitivity for testing what is nanogram quantities of OA on a standard curve.422
423
Poly-peptide chain composition of the complex424
Ultrafiltration425
In order to determine if BAMLET-like complexes can be formed with the peptides426
produced during in vitro simulated digestion an ultrafiltration step was employed427
using a 10 kDa UF membrane. Using size exclusion chromatography it was possible428
to determine that peptides were all of molecular weight less than 6.5 kDa, therefore429
the BAMLET-like complex (MW ~14,200 Da protein) is retained by the membrane430
while peptides and oleic acid were in the permeate (Figure 1B; Figure 5B). Analysis431
of the retentate of the UF sample of post-gastric a-LA shows that the OA present in432
the sample has a chemical shift of 5.3 which shows that oleic acid is bound to the433
protein (data not shown).434
435
HPLC436
Reversed-phase chromatography was used for both native protein analysis (C5), and437
peptide analysis (C18). C5 chromatography detects the loss in native protein and438
analysis of the samples showed that the peak obtained for α-LA had a retention time 439 
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of 11 minutes, which reduced slightly as digestion time progressed, suggesting that a440
slight decrease in hydrophobicity of the protein due to the loss of hydrophobic amino441
acids during hydrolysis. Quantification of the peak areas for α-LA before and after 442 
digestion shows that under the tested conditions ~60% of the native protein remains443
undigested after 30 minutes of digestion. (Figure 6A).444
445
SEC showed that there was a breakdown of α-LA into smaller peptides. After the 446 
addition of the digestive enzyme, proteolysis began to occur. The initial sample of α-447 
LA had a retention time of 28 minutes, and the intensity of the peak for native α-LA 448 
decreased as digestion time progressed, suggesting that there was still native protein449
present. There was an increase in the amount of breakdown products obtained during450
digestion (Figure 6B).451
452
C-18 chromatography was used for peptide analysis. There was a decrease in native453
protein content and a subsequent increase in peptide formation as digestion454
progressed. (Figure 6C).455
456
Electrophoresis457
SDS-PAGE analysis (Figure 1B) confirmed that the digest was composed of protein458
and peptides. UF with a 10 kDa membrane removed some peptide material however459
some remained in the retentate. The permeate consisted of peptides.460
461
Activity of the fractions462
All fractions that were isolated throughout the process were tested against lymphoma463
cell line U937 for their cytotoxic activity and their activity was compared to the464
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activity of BAMLET produced through chromatography. BAMLET had an LC50465
value of 9.15 M. The digested complex had an LC50 value of 14.08 M (Figure 7).466
The difference in the activity of the two samples can be related back to the oleic acid467
content within the samples. Testing of the fractions showed an enrichment of468
mononucleosomes and oligonucleosomes released into the cytoplasm of the treated469
cells, indicating that the cell death was as a result of apoptosis (data not shown).470
471
The UF permeate which contained the low molecular weight fractions from the digest472
was shown to contain the highest amount of oleic acid (Figure 3b) however473
bioactivity testing showed that this complex was not toxic to the cells in the tested474
concentrations.475
476
Discussion477
There has been speculation regarding the potential formation of HAMLET in the478
stomach of breast-fed infants (Svensson et al. 2003, Barbana et al. 2006). A recent479
study on the formation of BAMLET from denatured α-LA also alluded to the 480 
potential formation from α-LA from infant formula (Liskova et al. 2010). The data481
presented in this study indicates that a BAMLET-like complex, which is structurally482
and actively similar to BAMLET, can be formed under simulated gastric conditions.483
484
Recently, Tolin et al., 2010, published results that suggest that α-LA fragments can 485 
bind to oleic acid and induce apoptosis in cancer cells with comparative activity to486
BAMLET. These complexes are produced through mixing oleic acid with the487
fragments of α-LA to produce the complexes, suggesting that should α-LA undergo 488 
digestion it may bind oleic acid and be active. However these fragments are produced489
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under limited proteolysis and thus may not be representative of fragments that may be490
produced through in vitro and subsequently in vivo digestion. Comparatively491
speaking, there were in excess of 20 peptides formed with the conditions tested in this492
study, which is considerably greater than the 3 fragments produced through limited493
proteolysis. Thus while bioactive complexes can be formed through α-LA fragments, 494 
this was not observed with the fragments produced in this study.495
496
It was previously shown that unfolding is a pre-requisite for the conversion of α-LA to 497 
BAMLET; however unfolding alone is not enough to convert α-LA to its bioactive 498 
form (Svensson et al. 2003). The unfolding of α-LA results in an increase in its 499 
hydrophobicity (Pettersson-Kastberg et al. 2009) thus the current consensus is that it500
is the hydrophobic regions of α-LA act as binding sites for oleic acid, and that the 501 
formation of BAMLET is based on hydrophobic interactions502
(Tolin, et al. 2010). Sequencing of peptides derived from α-LA could therefore result 503 
in the identification of hydrophobic peptides, which may form HAMLET-like504
complexes. Other forces, such as electrostatic charge, may also have an impact on the505
formation of complexes, thus the negative charge of apo α-LA and α-LA in its A-state 506 
may impact the formation of the complex. The effect of the pH conditions on both the507
solubility and the charge of the oleic acid may also therefore have an affect on the508
formation of the complex. Hydrophobic interactions may be the initial cause of509
interaction, however this hydrophobic interaction alone is not enough to produce the510
complex as at pH 2.5 the oleic acid present was not enough to have a cytotoxic effect511
against the cells. A secondary effect is needed to partially refold the α-LA in order to 512 
convert it to its bioactive form. Thus either the structural change in the protein (partial513
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refolding) or the change in the charge on the protein had an impact on the complex514
formation.515
516
Another important factor to consider when determining the formation of the complex517
is the molecular state of oleic acid. Oleic acid has no charge below its pKa, and while518
the pKa of oleic acid is approximately pH 4.8, and this can change depending on519
osmotic conditions. Thus should the electrostatic force between the protein and the520
fatty acid could be a factor in the production of the complex, the oleic acid will not be521
in a suitable state to bind to the protein. Oleic acid is also pH dependant in that it can522
interchange between its acid state and its oleate (salt form) state. Therefore when523
looking at the complex formation it is necessary to not only look at the conformation524
of the protein, but also of the fatty acid state.525
526
The structure of the complex remains a point of interest. There have been many527
structural studies on HAMLET and HAMLET-like complexes, the most recent by528
Pettersson-Kastberg et al in 2009 where they produced a perpetually molten-globule529
form of α-LA (rHLA
all-Ala-OA) and used it to produce a HAMLET-like complex.530
NMR spectroscopy of this complex and HAMLET produced through chromatography531
showed there were no chemical shifts in the upfield region of the spectra, suggesting a532
lack of tertiary structure within the protein. A similar structure has also previously533
been observed in other studies (Casbarra et al. 2004). However as shown in Figure 4,534
there are many peaks seen in the upfield region of the spectra, which corresponds to a535
native-like structure. We speculate that the reason lies in the fact that the alpha-536
lactalbumin-fatty acid complex forms a continuum of various partially-unfolded states537
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of varying degrees that make up the entire population (Pettersson-Kastberg et al.538
2009).539
540
The indigenous properties of human milk are also important for the formation of the541
complex. The presence of gastric lipase in the milk means that there will be elevated542
levels of lipolysis in breast-fed infants (Jensen 1995). The second important factor in543
the formation of the complex is the digestive tract of infants. The conditions are544
favourable for complex formation as the pH decreases over time (Mitchell et al.545
2001), which are unfavourable for proteolysis, thus less proteolysis will occur. The546
pH decrease also promotes lipolysis prior to protein unfolding thus free fat will be547
present prior to protein refolding.548
549
The resistance of α-LA to proteolysis in the presence of oleic acid (Casberra et al,550
2004) is another interesting factor. This study has shown that as α-LA is converted to 551 
its bioactive form, 60% of the native protein remains. This is a significant finding, as552
conversion to the bioactive form is not seen with α-LA peptide fragments. It is also an 553 
inherent characteristic of α-LA that it is more resistant to tryptic hydrolysis than other 554 
whey proteins (Polverino de Laureto et al. 1995). Thus once peptic hydrolysis is555
complete, α-LA will remain more stable in the GI tract.  556 
557
The binding of OA to α-LA also results in the stabilisation of α-LA. α-LA in its apo/a-558 
state is inherently unstable as it does not have a co-factor bound (Halskau et al. 2002).559
Thus the binding of OA to the protein may also stabilise it to intestinal digestion.560
561
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Activity analysis of the digested complex compared to BAMLET yielded interesting562
results. Samples were solubilised in RPMI media with regards to protein content.563
Thus their oleic acid content is different based on oleic acid molar ratio estimation.564
BAMLET produced through chromatography has a lower LC50 value than the565
BAMLET-like complex produced through digestion. As the samples are structurally566
homologous it can be concluded that the difference in activity may be as a result of567
the difference in oleic acid levels, thus suggesting that OA is the active component of568
H/BAMLET and α-LA acts as a mule to deliver OA to the cells. This confirms 569 
previous results including (Wilhelm, Darinskas et al. 2009) and Permyakov et al,570
2012.571
572
This study also raises the potential for the production of BAMLET without573
chromatography. Many methods have been suggested for the formation of574
H/BAMLET without the use of chromatography, including mixing at room575
temperature and titrating with OA to its critical micelle concentration (Knyazeva et al.576
2008), mixing at elevated temperatures (Zhang et al. 2009), and simple mixing in577
solution (Spolaore et al. 2010, Brodkorb & Liskova, 2009).578
579
Thus it can be concluded from this study that under the tested simulated gastric580
conditions, a complex that is structurally and actively homologous to that of581
BAMLET can be produced.582
583
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584
Abbreviation Symbol Analyses
Stage 1: Formulation of milk Structural Analysis
α -Lactalbumin  α -LA  Fluorescence
Oleic acid dissolved in ethanol OA  FTIR
Apo α -Lactalbumin Apo  NMR
Stage 2: Gastric phase – pH 2.5
Addition of HCl to mimic pH conditions (as per figure 1A) Gastric α -LA  OA Content
Addition of pepsin FTIR
Stage 3: Post-gastric phase – pH 7 NMR
Addition of NaOH to bring pH to neutral conditions Post-gastric α -LA  GC
Stage 4: Ultrafiltration
Retentate  Bioactivity
Ultrafiltration of digest through a 10 kDa membrane at pH 7
Permeate  Testing on U937 cells
Compared to
BAMLET produced
through
chromatography
(BAMLET )
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Table 1: Outline of different stages before, during and after in vitro gastric digestion, with corresponding samples and abbreviations used585
throughout the study586
587
588
589
Figure 1: A) pH gradient used during simulated gastric digestion with highlighted590
areas: I) the optimum pH range for gastric lipolysis; II) the point at which α-LA 591 
unfolding commences, III) the pH range of highest gastric proteolysis and IV) the pH592
for α-lactalbumin re-folding. B) SDS-PAGE of 1- α-LA 2- Post-gastric α -LA 3- UF 593 
Retentate 4- UF Permeate. MW – protein molecular weight markers 250 – 10 kDa.594
595
596
597
598
599
600
601
602
Figure 2: A) Intrinsic fluorescence spectrum of Gastric α-LA (); for comparison,603
spectra of holo () and apo () α-LA are also shown. The fluorescence maximum 604 
for Gastric α-LA was 349nm, for holo α-LA 327 nm and for apo α-LA 349 nm,   605 
B) Intrinsic fluorescence spectrum of Post-Gastric α-LA at pH 7 (); for comparison,606
spectra of holo α-LA (), and apo α-LA () and BAMLET () are also shown.607
C) ANS fluorescence spectra of Gastric α-LA (); Post-Gastric α-LA (); for608
comparison, spectra of apo α-LA (); BAMLET () and holo α-LA () are also609
shown.610
611
612
Figure 3: Amide I region of vector-normalised FTIR of Gastric α-LA at pH 2.5 ()613
and Post-Gastric α-la at pH 7 () ; native α-LA (); BAMLET () and oleic acid614
() shown for comparison.615
616
617
Figure 4: 1H-NMR spectra of (a) α-LA; (b) BAMLET produced through 618 
chromatography; (c) Post-gastric α -LA; (d) Gastric α-LA. I and II are magnified 619 
section of the spectra corresponding to the oleic acid and aliphatic protein region of620
the spectra, respectively.621
622
623
624
625
626
627
628
Figure 5: Vector-normalised region of FTIR spectra corresponding to oleic acid629
during (A) simulated gastric digestion and (B) subsequent fractionation by ultra-630
filtration. (A): Gastric α-LA (), Post-Gastric α-LA (); for comparison OA alone631
(); α-LA () and BAMLET () are also shown.632
(B): OA spectra for the different stages during ultra-filtration after digestion showing633
the permeate with an increased OA content (-) and the retentate (), along with Post-634
Gastric α-LA prior ultra-filtration (), holo α-LA ().635
636
637
638
639
640
641
Figure 6: HPLC chromatographs of α-LA (solid line) and post-gastricd α-LA (dashed 642 
line) using (a) Native protein-reversed phase ; (b) size exclusion chromatography; (c)643
C18 reversed phase. In each case a decrease in native protein content can be observed,644
and a subsequent increase in peptide formation.645
646
648
650
whare652
the error bars???654
656
Figure 7: Cytotoxicity658
660
663
665
667
669
671
Figure 7: Cytotoxicity against U937 cells tested with alamarBlue after a 24 hour672
incubation with of A) the digested complex (■), BAMLET (), and α-LA (♦); and B) 673 
the UF retentate (▲), the UF permeate (-), BAMLET (■) and α-LA (♦).  Data are the 674 
means of three independent measurements with SDs represented by vertical bars.675
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